EUVIMEDEUVIMED entdecken
EditorialKommentar

Development of a Staphylococcus aureus Vaccine: An Ongoing Journey

Richard A Proctor

Clinical Infectious Diseases · 26.07.2023 · 77 (2) · 321-322

DOI: 10.1093/cid/ciad217 ↗

Kurz gefasst

Editorial in der Zeitschrift Clinical Infectious Diseases, online erschienen am 29.04.2023. Verfasst von Richard A Proctor. Beteiligte Einrichtung: Departments of Medicine and Medical Microbiology/Immunology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Staphylococcus aureus, Vaccines. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The failure of the 4-antigen vaccine to prevent Staphylococcus aureus deep surgical site infections and bacteremia following posterior spinal fusion in the Staphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) trial is another disappointment. However, the information provided by Hassanzadeh et al is extremely valuable as it can instruct future clinical trials. The rationale for this vaccine was based on enhancing opsonophagocytic activity (OPA) in preclinical animal models [1]. Several other anti-S. aureus vaccines based on enhancing OPA have also failed to protect humans [2]. While enhancing OPA has been a highly successful approach in the development of other bacterial vaccines, it has not improved outcomes in humans, perhaps because there is already sufficient prevaccination OPA in most humans but also because nonopsonic activation of phagocytes alone may be sufficient (reviewed in [2–4]). Relying on enhanced OPA to protect humans was perhaps overly optimistic as we learn more about the tremendous complexity of the host–pathogen interactions with S. aureus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Staphylococcus aureusVaccinesHumansInpatientsVaccine EfficacyLongitudinal Studies

Stichwörter der Autor:innen

Staphylococcus aureusimmunityvaccine

Substanzen

Vaccines

Autor:innen und Institutionen

  • Departments of Medicine and Medical Microbiology/Immunology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Zitieren

APA

Proctor, R. A. (2023). Development of a Staphylococcus aureus Vaccine: An Ongoing Journey. Clinical Infectious Diseases, 77(2), 321-322. https://doi.org/10.1093/cid/ciad217

Vancouver

Proctor RA. Development of a Staphylococcus aureus Vaccine: An Ongoing Journey. Clinical Infectious Diseases. 2023;77(2):321-322. doi:10.1093/cid/ciad217

BibTeX
@article{Proctor2023,
  author = {Proctor, Richard A},
  title = {Development of a Staphylococcus aureus Vaccine: An Ongoing Journey},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {77},
  number = {2},
  pages = {321--322},
  doi = {10.1093/cid/ciad217}
}
Kostenlos starten →